Navigation Links
Stallergenes : 3rd Quarter Sales Up 17%: 9- Month Cumulative Sales Up 17%
Date:10/11/2007

PARIS, October 11 /PRNewswire-FirstCall/ --

(EUR millions) 2007 2006 07/06

%Sales %Sales %

change

Southern Europe (1) 20.63 70.6 17.61 70.7 17

Other EU countries (2) 7.07 24.2 6.06 24.4 17

Other markets 1.51 5.2 1.22 4.9 24

SLIT 22.13 75.8 18.14 72.9 22

SCIT 5.96 20.4 5.60 22.5 6

Other products 1.12 3.8 1.15 4.6 (3)

Total Q3 sales 29.21 100.0 24.89 100.0 17

Southern Europe (1) 77.16 74.2 65.71 73.8 17

Other EU countries (2) 22.83 21.9 19.78 22.2 15

Other markets 4.02 3.9 3.60 4.0 12

SLIT 81.88 78.7 67.55 75.8 21

SCIT 17.78 17.1 17.23 19.3 3

Other products 4.35 4.2 4.31 4.8 1

9-month cumulated sales 104.01 100.0 89.09 100.0 17

(1) Portugal, Spain, France, Italy, Greece;

(2) Switzerland included

Sales growth and financial position

2007 3rd quarter sales registered further significant growth in all markets (+17%, vs +9% in 2006). The most vigorous market segment remained sublingual route desensitization (SLIT, +22%). Subcutaneous route sales (SCIT) increased by 6%. Cumulative sales for the first nine months of the year increased by 17% (vs +13% in 2006).

The financial position improved. Net debt declined 40% from net debt at 30 September 2006.

Significant 3rd quarter transactions and events

The new allergen production facility has been completed. Collection and validation operations are being implemented within the planned timeframe.

The market authorisation procedure for the ORALAIR(R) Grasses allergen tablet by the P.E.I. German agency is still ongoing. Management is confident the procedure will soon be completed.

Outlook for the current year

The Group now provides guidance of 12% to 14% full-year sales growth and profitability close to that of 2006 in absolute value.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitization treatments for the prevention and cure of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma.

A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes more than 15% of its sales to Research and Development and is today fully involved in the development of a new therapeutic family, the sublingual desensitization tablets.

With a registered office in France, Stallergenes markets its products in approximately 40 countries. Stallergenes realised 2006 sales of EUR 126.5 million, of which half outside France.

Stallergenes' shares are listed on Eurolist Compartment B of the Euronext Paris Stock Exchange.

ISIN code: FR0000065674, Reuters code: GEN.PA, Bloomberg code: GEN.FP

For additional information on Stallergenes, please visit our website: http://finance.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Midwest life science stocks sizzle in a tepid first quarter
2. CIOs looking to hire more IT workers in second quarter
3. Fiserv posts 30 percent quarterly loss
4. Sonic Foundry reports first cash-positive quarter
5. Venture capital above $6B for third straight quarter
6. Third Wave reports $5.2M third quarter loss
7. Inventions could fall prey to Monday morning quarterbacking
8. Merge fails to file quarterly financial report
9. Rexnord to slash debt after quarterly loss
10. Johnson Controls reports record quarterly sales
11. Sonic Foundry reports quarterly loss, higher Mediasite sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... -- There is no saying when exactly ... pressures in pricing and lack in consumer confidence. One ... - numerous opportunities are up for grabs but this ... four names in this sector: Portola Pharmaceuticals Inc. (NASDAQ: ... VTAE ), Anthera Pharmaceuticals Inc. (NASDAQ: ...
(Date:5/18/2016)... (PRWEB) , ... May 18, 2016 , ... Tech ... the Luis Villalobos Award to Cognition Therapeutics at the annual ACA Summit last week ... that is financed by one of ACA’s member angel groups. It is the highest ...
(Date:5/18/2016)... Washington, PA (PRWEB) , ... May 18, 2016 ... ... at least 1,200 hospitalizations are a direct result of asthma complications.* Costing more ... challenge across the country. , “For too many, the suffering ...
(Date:5/17/2016)... ... May 17, 2016 , ... DryLet, LLC, a biotechnology company ... it will be showcasing ManureMagic™ at booth V1061 at the World Pork Expo, ... Street Journal last year and more recently made news as the results were ...
Breaking Biology Technology:
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):